17.4 USD
+0.61 (+3.62%)
Taking everything into account, PRTC scores 3 out of 10 in our fundamental rating. PRTC was compared to 530 industry peers in the Biotechnology industry. The financial health of PRTC is average, but there are quite some concerns on its profitability. While showing a medium growth rate, PRTC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PRTC had negative earnings in the past year.
PRTC had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PRTC reported negative net income in multiple years.
In the past 5 years PRTC always reported negative operating cash flow.
1.2 Ratios
PRTC has a Return On Assets of 9.16%. This is amongst the best in the industry. PRTC outperforms 93.58% of its industry peers.
PRTC's Return On Equity of 13.48% is amongst the best of the industry. PRTC outperforms 94.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROIC | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRTC has a better Profit Margin (792.96%) than 99.25% of its industry peers.
PRTC's Profit Margin has declined in the last couple of years.
PRTC does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRTC has been reduced compared to 1 year ago.
Compared to 5 years ago, PRTC has less shares outstanding
The debt/assets ratio for PRTC is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.66, we must say that PRTC is in the distress zone and has some risk of bankruptcy.
PRTC's Altman-Z score of 1.66 is fine compared to the rest of the industry. PRTC outperforms 65.66% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that PRTC is not too dependend on debt financing.
PRTC's Debt to Equity ratio of 0.05 is in line compared to the rest of the industry. PRTC outperforms 41.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.66 |
ROIC/WACCN/A
WACC8.58%
2.3 Liquidity
A Current Ratio of 8.49 indicates that PRTC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.49, PRTC is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
PRTC has a Quick Ratio of 8.49. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
PRTC's Quick ratio of 8.49 is fine compared to the rest of the industry. PRTC outperforms 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 168.34% over the past year.
The earnings per share for PRTC have been decreasing by -32.49% on average. This is quite bad
The Revenue has grown by 1265.60% in the past year. This is a very strong growth!
PRTC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.22% yearly.
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
3.2 Future
Based on estimates for the next years, PRTC will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.77% on average per year.
The Revenue is expected to grow by 223.14% on average over the next years. This is a very strong growth
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRTC's earnings are expected to decrease with -17.46% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
5. Dividend
5.1 Amount
PRTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PRTC (1/7/2026, 4:30:01 PM)
17.4
+0.61 (+3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.59%
Inst Owner Change0%
Ins Owners4.86%
Ins Owner ChangeN/A
Market Cap420.53M
Revenue(TTM)6.39M
Net Income(TTM)50.68M
Analysts84
Price Target67.76 (289.43%)
Short Float %0.03%
Short Ratio1.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 65.8 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.12 | ||
| P/tB | 1.12 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.27
EYN/A
EPS(NY)-6.52
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.26
BVpS15.56
TBVpS15.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 | ||
| Altman-Z | 1.66 |
F-Score7
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)9.91%
Cap/Depr(5y)37.78%
Cap/Sales(3y)7.17%
Cap/Sales(5y)20.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
EBIT growth 1Y13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.57%
EBIT Next 3Y-5.38%
EBIT Next 5Y3.12%
FCF growth 1Y36.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.98%
OCF growth 3YN/A
OCF growth 5YN/A
PURETECH HEALTH PLC - ADR / PRTC FAQ
Can you provide the ChartMill fundamental rating for PURETECH HEALTH PLC - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to PRTC.
Can you provide the valuation status for PURETECH HEALTH PLC - ADR?
ChartMill assigns a valuation rating of 0 / 10 to PURETECH HEALTH PLC - ADR (PRTC). This can be considered as Overvalued.
Can you provide the profitability details for PURETECH HEALTH PLC - ADR?
PURETECH HEALTH PLC - ADR (PRTC) has a profitability rating of 3 / 10.
What is the financial health of PURETECH HEALTH PLC - ADR (PRTC) stock?
The financial health rating of PURETECH HEALTH PLC - ADR (PRTC) is 5 / 10.